ARD 111421Alternative Names: AR-D111421
Latest Information Update: 15 Sep 2000
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Vasoactive intestinal peptide receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 15 Sep 2000 Discontinued-II for Asthma (Unknown route)
- 27 Jan 2000 New profile
- 27 Jan 2000 Phase-II clinical trials for Asthma (Unknown route)